Literature DB >> 29582697

Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.

Katherine Hoversten1, Rangit Vallapureddy2, Terra Lasho2, Christy Finke2, Rhett Ketterling3, Curtis Hanson4, Naseema Gangat2, Ayalew Tefferi2, Mrinal M Patnaik2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29582697      PMCID： PMC6173652          DOI： 10.1080/10428194.2018.1452212

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik; Daniela Barraco; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-12-07       Impact factor: 10.047

Review 2.  Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2016-06       Impact factor: 10.047

3.  Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria.

Authors:  S Kaddu; P Zenahlik; C Beham-Schmid; H Kerl; L Cerroni
Journal:  J Am Acad Dermatol       Date:  1999-06       Impact factor: 11.527

Review 4.  Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

Authors:  Rahel A Mathew; John M Bennett; Jane Jijun Liu; Rami S Komrokji; Jeffrey E Lancet; Mojdeh Naghashpour; Jane L Messina; Alan F List; Lynn C Moscinski; Ling Zhang
Journal:  Leuk Res       Date:  2011-07-22       Impact factor: 3.156

5.  Granulocytic sarcoma: 32 cases and review of the literature.

Authors:  Semra Paydas; Suzan Zorludemir; Melek Ergin
Journal:  Leuk Lymphoma       Date:  2006-12

Review 6.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

7.  Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia.

Authors:  C R Bradford; S R Smith; J P Wallis
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

8.  Extramedullary hematopoiesis in a sentinel lymph node as an early sign of chronic myelomonocytic leukemia.

Authors:  Joslin M Bowen; Anamarija M Perry; Erin Quist; Mojtaba Akhtari
Journal:  Case Rep Pathol       Date:  2015-04-16

9.  Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.

Authors:  M M Patnaik; T L Lasho; P Vijayvargiya; C M Finke; C A Hanson; R P Ketterling; N Gangat; A Tefferi
Journal:  Blood Cancer J       Date:  2016-01-15       Impact factor: 11.037
  9 in total
  2 in total

1.  Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Authors:  Prateek Pophali; Pedro Horna; Terra L Lasho; Christy M Finke; Rhett P Ketterling; Naseema Gangat; David Nagorney; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2018-10-05       Impact factor: 10.047

2.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.